Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Gammagard Liquid for infection prevention in adults with multiple myeloma receiving teclistamab
MOH_2026-05-31_016857Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Apr 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of polyvalent human immunoglobulin in secondary immunodeficiency (SID) and Infection prevention (IPC) (2 arms), sponsored by Takeda. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
secondary immunodeficiency (SID)Infection prevention (IPC)
Beyond the preview
Go deeper on MOH_2026-05-31_016857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-31_016857.